| **Empirical** | | | | **Prescribed** | | | **Top Model: Data Type(s) Prediction** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Primary Disease** | **Lineage Subtype** | **Cell Line** | **AAC** | **Highest AAC** | **Cancer** | **Drug** |
| Bile Duct Cancer | Cholangiocarcinoma | HUCCT1 | 0.314 | 0.299 | Kidney Cancer | Temsirolimus | MUT 0.31 |
| SNU1079 | 0.545 | 0.466 | Lymphoma | Vorinostat | CNV + EXP 0.469 |
| 0.422 | 0.304 | Thyroid Cancer | Vandetanib | MUT + EXP 0.422 |
| 0.365 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP + METAB 0.366 |
| 0.279 | 0.253 | Sarcoma | Pazopanib | PROT + MIRNA 0.276 |
| SNU478 | 0.387 | 0.304 | Thyroid Cancer | Vandetanib | MIRNA + RPPA 0.357 |
| Bladder Cancer | Bladder Carcinoma | 253J | 0.364 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP + METAB 0.361 |
| 0.273 | 0.253 | Sarcoma | Pazopanib | MIRNA + RPPA 0.206 |
| 5637 | 0.358 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA 0.359 |
| CAL29 | 0.436 | CNV + EXP 0.401 |
| 0.289 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + METAB 0.263 |
| 0.199 | 0.177 | Breast Cancer | Tamoxifen | MUT + EXP 0.166 |
| JMSU1 | 0.352 | 0.282 | Pancreatic Cancer | Sunitinib | MIRNA + METAB + HIST + RPPA 0.357 |
| 0.339 | 0.253 | Sarcoma | Pazopanib | CNV + PROT 0.29 |
| 0.123 | 0.120 | Skin Cancer | Sonidegib | MUT + PROT 0.044 |
| KU1919 | 0.147 | CNV + PROT 0.08 |
| RT112 | 0.304 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + PROT 0.301 |
| 0.261 | 0.253 | Sarcoma | Pazopanib | CNV + EXP 0.252 |
| SCABER | 0.496 | 0.496 | Leukemia | Ibrutinib | MUT + EXP 0.52 |
| TCCSUP | 0.462 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + HIST 0.448 |
| UBLC1 | 0.483 | 0.304 | Thyroid Cancer | Vandetanib | PROT + HIST 0.483 |
| 0.282 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + METAB 0.283 |
| UMUC1 | 0.354 | 0.253 | Sarcoma | Pazopanib | MUT + EXP 0.289 |
| Bone Cancer | Ewing Sarcoma | A673 | 0.313 | 0.282 | Pancreatic Cancer | Sunitinib | PROT + RPPA 0.312 |
| MHHES1 | 0.429 | 0.299 | Kidney Cancer | Temsirolimus | METAB 0.427 |
| 0.380 | 0.363 | Breast Cancer | Olaparib | CNV + EXP 0.417 |
| 0.292 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + MIRNA 0.293 |
| SKES1 | 0.329 | PROT + HIST 0.335 |
| Osteosarcoma | SJSA1 | 0.385 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.39 |
| 0.195 | 0.177 | Breast Cancer | Tamoxifen | MUT + CNV 0.152 |
| U2OS | 0.378 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + METAB 0.378 |
| 0.287 | 0.282 | Pancreatic Cancer | Sunitinib | PROT + RPPA 0.285 |
| Brain Cancer | Glioma | 42MGBA | 0.492 | 0.367 | Breast Cancer | Alpelisib | MUT + EXP 0.311 |
| AM38 | 0.684 | HIST + RPPA 0.73 |
| 0.656 | 0.496 | Leukemia | Ibrutinib | MUT + CNV 0.503 |
| CAS1 | 0.359 | 0.299 | Kidney Cancer | Temsirolimus | EXP + RPPA 0.333 |
| GAMG | 0.340 | MUT + EXP 0.336 |
| KALS1 | 0.354 | MUT + HIST 0.356 |
| KG1C | 0.424 | 0.293 | Lung Cancer | Dabrafenib | MUT + EXP 0.389 |
| KNS60 | 0.231 | 0.177 | Breast Cancer | Tamoxifen | MUT + EXP 0.206 |
| KNS81 | 0.320 | 0.299 | Kidney Cancer | Temsirolimus | MUT + PROT 0.291 |
| 0.213 | 0.177 | Breast Cancer | Tamoxifen | CNV + EXP 0.211 |
| NMCG1 | 0.185 | MIRNA 0.108 |
| SF268 | 0.184 | MUT + EXP 0.194 |
| SF295 | 0.344 | 0.299 | Kidney Cancer | Temsirolimus | CNV + RPPA 0.335 |
| SF539 | 0.179 | 0.177 | Breast Cancer | Tamoxifen | CNV + EXP 0.17 |
| SNU466 | 0.368 | 0.367 | Lymphoma | Bortezomib | MIRNA + RPPA 0.354 |
| SW1088 | 0.386 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + METAB + HIST + RPPA 0.386 |
| Medulloblastoma | ONS76 | 0.330 | CNV + EXP 0.318 |
| Breast Cancer | Breast Adenocarcinoma | AU565 | 0.623 | 0.496 | Leukemia | Ibrutinib | EXP + MIRNA 0.588 |
| EFM192A | 0.658 | METAB + RPPA 0.595 |
| 0.367 | 0.367 | Breast Cancer | Alpelisib | CNV + EXP 0.364 |
| Breast Carcinoma | CAL51 | 0.437 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP 0.438 |
| CAMA1 | 0.359 | PROT + METAB 0.358 |
| DU4475 | 0.991 | 0.901 | Skin Cancer | Trametinib | MIRNA + RPPA 0.855 |
| 0.953 | 0.293 | Lung Cancer | Dabrafenib | MUT + EXP 0.777 |
| 0.447 | 0.367 | Lymphoma | Bortezomib | MUT + MIRNA 0.385 |
| 0.370 | 0.360 | Skin Cancer | Vemurafenib | MUT + CNV 0.346 |
| 0.310 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + EXP 0.311 |
| HCC1569 | 0.567 | 0.299 | Kidney Cancer | Temsirolimus | METAB + RPPA 0.598 |
| 0.200 | 0.120 | Skin Cancer | Sonidegib | CNV + MIRNA 0.054 |
| 0.177 | 0.177 | Breast Cancer | Tamoxifen | MUT + CNV 0.133 |
| HS578T | 0.356 | 0.253 | Sarcoma | Pazopanib | CNV + EXP 0.334 |
| KPL1 | 0.311 | 0.299 | Kidney Cancer | Temsirolimus | METAB 0.288 |
| MCF7 | 0.484 | HIST + RPPA 0.485 |
| 0.356 | 0.356 | Breast Cancer | Fulvestrant | CNV + PROT 0.202 |
| MDAMB453 | 0.132 | 0.120 | Skin Cancer | Sonidegib | MUT + EXP 0.105 |
| SKBR3 | 0.603 | 0.496 | Leukemia | Ibrutinib | CNV + EXP 0.586 |
| 0.367 | 0.367 | Breast Cancer | Alpelisib | CNV + METAB 0.359 |
| Breast Ductal Carcinoma | CAL148 | 0.403 | 0.299 | Kidney Cancer | Temsirolimus | HIST + RPPA 0.404 |
| HCC1143 | 0.387 | EXP + PROT 0.386 |
| HCC1419 | 0.511 | 0.496 | Leukemia | Ibrutinib | MUT + RPPA 0.502 |
| HCC1954 | 0.631 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + HIST 0.612 |
| HCC2218 | 0.629 | 0.629 | Breast Cancer | Lapatinib | MIRNA + HIST 0.598 |
| MDAMB157 | 0.363 | 0.363 | Olaparib | MUT + CNV 0.396 |
| ZR751 | 0.448 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + RPPA 0.448 |
| ZR7530 | 0.585 | 0.496 | Leukemia | Ibrutinib | HIST + RPPA 0.585 |
| Colon/Colorectal Cancer | Colorectal Adenocarcinoma | C2BBE1 | 0.357 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP 0.359 |
| CCK81 | 0.558 | 0.496 | Leukemia | Ibrutinib | MUT + MIRNA 0.582 |
| 0.304 | 0.304 | Thyroid Cancer | Vandetanib | MIRNA + METAB + HIST + RPPA 0.301 |
| CL34 | 0.594 | 0.592 | Lung Cancer | Crizotinib | PROT + MIRNA 0.594 |
| COLO678 | 0.318 | 0.304 | Thyroid Cancer | Vandetanib | MUT + MIRNA 0.318 |
| GP2D | 0.561 | 0.367 | Breast Cancer | Alpelisib | MUT + EXP 0.412 |
| HCT15 | 0.305 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + PROT 0.269 |
| HT115 | 0.352 | 0.304 | Thyroid Cancer | Vandetanib | MUT + CNV 0.351 |
| KM12 | 0.452 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + MIRNA 0.264 |
| 0.123 | 0.120 | Skin Cancer | Sonidegib | MUT + CNV 0.039 |
| LOVO | 0.345 | 0.299 | Kidney Cancer | Temsirolimus | MUT 0.346 |
| 0.327 | 0.304 | Thyroid Cancer | Vandetanib | MIRNA + HIST 0.329 |
| MDST8 | 0.378 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + RPPA 0.378 |
| NCIH716 | 0.572 | 0.554 | Axitinib | PROT + MIRNA 0.45 |
| 0.481 | 0.253 | Sarcoma | Pazopanib | MUT + PROT 0.38 |
| 0.375 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP 0.353 |
| SKCO1 | 0.396 | 0.299 | Kidney Cancer | Temsirolimus | PROT + METAB 0.384 |
| SNU1033 | 0.397 | 0.367 | Breast Cancer | Alpelisib | MUT 0.428 |
| SNU407 | 0.307 | 0.299 | Kidney Cancer | Temsirolimus | METAB 0.309 |
| SNUC2A | 0.340 | MIRNA + RPPA 0.337 |
| SW1116 | 0.364 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP 0.376 |
| SW1417 | 0.311 | MUT + RPPA 0.271 |
| SW1463 | 0.253 | Sarcoma | Pazopanib | MIRNA + METAB 0.182 |
| SW48 | 0.365 | 0.282 | Pancreatic Cancer | Sunitinib | PROT + MIRNA 0.361 |
| 0.310 | 0.299 | Kidney Cancer | Temsirolimus | PROT + METAB 0.312 |
| SW948 | 0.379 | 0.379 | Colon/Colorectal Cancer | Regorafenib | PROT + MIRNA 0.316 |
| T84 | 0.190 | 0.177 | Breast Cancer | Tamoxifen | CNV + EXP 0.184 |
| Endometrial/Uterine Cancer | Endometrial Adenocarcinoma | AN3CA | 0.385 | 0.253 | Sarcoma | Pazopanib | CNV + EXP 0.317 |
| HEC265 | 0.386 | 0.385 | Kidney Cancer | Sorafenib | MUT + PROT 0.316 |
| 0.269 | 0.177 | Breast Cancer | Tamoxifen | MUT + PROT 0.323 |
| HEC59 | 0.373 | 0.299 | Kidney Cancer | Temsirolimus | PROT + METAB 0.374 |
| JHUEM2 | 0.564 | MIRNA + HIST 0.559 |
| 0.523 | 0.363 | Breast Cancer | Olaparib | CNV + EXP 0.395 |
| 0.351 | 0.253 | Sarcoma | Pazopanib | CNV + PROT 0.344 |
| JHUEM3 | 0.319 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP 0.305 |
| Endometrial Adenosquamous | RL952 | 0.415 | 0.299 | Kidney Cancer | Temsirolimus | CNV + HIST 0.412 |
| Esophageal Cancer | Esophagus Squamous | KYSE140 | 0.190 | 0.177 | Breast Cancer | Tamoxifen | CNV + MIRNA 0.18 |
| KYSE410 | 0.498 | 0.299 | Kidney Cancer | Temsirolimus | MUT + PROT 0.497 |
| OE21 | 0.399 | 0.304 | Thyroid Cancer | Vandetanib | MUT + EXP 0.396 |
| TE10 | 0.301 | 0.299 | Kidney Cancer | Temsirolimus | MUT + MIRNA 0.297 |
| TE4 | 0.208 | 0.177 | Breast Cancer | Tamoxifen | CNV + MIRNA 0.226 |
| TE5 | 0.405 | 0.367 | Alpelisib | MUT + EXP 0.391 |
| TE6 | 0.193 | 0.177 | Tamoxifen | CNV + EXP 0.193 |
| TE8 | 0.223 | CNV + EXP 0.194 |
| Fibroblast | Fibroblast Bone | HS888T | 0.306 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + MIRNA 0.304 |
| Fibroblast Skin | HS940T | 0.326 | MUT + EXP 0.315 |
| Gastric Cancer | Gastric Adenocarcinoma | 2313287 | 0.402 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + RPPA 0.403 |
| FU97 | 0.318 | MIRNA + HIST 0.322 |
| HGC27 | 0.492 | 0.367 | Breast Cancer | Alpelisib | MUT + RPPA 0.429 |
| 0.320 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + MIRNA 0.318 |
| 0.193 | 0.177 | Breast Cancer | Tamoxifen | CNV + HIST 0.195 |
| IM95 | 0.384 | 0.367 | Alpelisib | CNV + METAB 0.37 |
| KATOIII | 0.305 | 0.304 | Thyroid Cancer | Vandetanib | MUT + PROT 0.31 |
| 0.284 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + MIRNA 0.283 |
| 0.271 | 0.253 | Sarcoma | Pazopanib | MUT + PROT 0.251 |
| LMSU | 0.267 | CNV + EXP 0.26 |
| NCCSTCK140 | 0.541 | 0.496 | Leukemia | Ibrutinib | MUT + CNV 0.548 |
| 0.460 | 0.367 | Breast Cancer | Alpelisib | CNV + RPPA 0.462 |
| NCIN87 | 0.644 | 0.629 | Lapatinib | PROT + HIST 0.597 |
| 0.394 | 0.299 | Kidney Cancer | Temsirolimus | PROT + MIRNA 0.393 |
| NUGC3 | 0.306 | CNV 0.306 |
| NUGC4 | 0.348 | 0.304 | Thyroid Cancer | Vandetanib | CNV + MIRNA 0.354 |
| 0.314 | 0.299 | Kidney Cancer | Temsirolimus | EXP + MIRNA 0.313 |
| SNU16 | 0.444 | 0.253 | Sarcoma | Pazopanib | EXP + MIRNA 0.362 |
| 0.321 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + MIRNA 0.319 |
| SNU216 | 0.408 | 0.367 | Breast Cancer | Alpelisib | MUT + CNV 0.405 |
| Gastric Small Cell | ECC10 | 0.485 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.486 |
| 0.376 | 0.367 | Breast Cancer | Alpelisib | MIRNA + METAB 0.375 |
| Head and Neck Cancer | Upper Aerodigestive Squamous | BHY | 0.322 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP 0.32 |
| BICR31 | 0.344 | 0.304 | Thyroid Cancer | Vandetanib | CNV + MIRNA 0.348 |
| CAL33 | 0.368 | 0.367 | Breast Cancer | Alpelisib | PROT + MIRNA 0.363 |
| 0.305 | 0.304 | Thyroid Cancer | Vandetanib | CNV + HIST 0.303 |
| DETROIT562 | 0.354 | 0.299 | Kidney Cancer | Temsirolimus | CNV + PROT 0.35 |
| HSC4 | 0.325 | CNV + PROT 0.325 |
| PECAPJ15 | 0.359 | 0.304 | Thyroid Cancer | Vandetanib | MUT + EXP 0.318 |
| PECAPJ49 | 0.323 | MUT + RPPA 0.321 |
| SCC25 | 0.604 | 0.496 | Leukemia | Ibrutinib | CNV + EXP 0.615 |
| 0.407 | 0.299 | Kidney Cancer | Temsirolimus | EXP + RPPA 0.408 |
| SCC4 | 0.424 | 0.304 | Thyroid Cancer | Vandetanib | CNV + METAB 0.362 |
| SNU1076 | 0.329 | 0.299 | Kidney Cancer | Temsirolimus | METAB + HIST 0.332 |
| 0.322 | 0.304 | Thyroid Cancer | Vandetanib | EXP + METAB 0.316 |
| SNU1214 | 0.344 | MUT + METAB 0.344 |
| YD10B | 0.508 | MUT + EXP 0.506 |
| 0.371 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + HIST 0.364 |
| 0.348 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP + METAB 0.345 |
| YD15 | 0.327 | MUT + EXP 0.321 |
| YD8 | 0.355 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP 0.348 |
| Kidney Cancer | Malignant Rhabdoid Tumor | G402 | 0.554 | 0.554 | Axitinib | MIRNA + HIST 0.399 |
| 0.472 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP 0.45 |
| 0.438 | 0.253 | Sarcoma | Pazopanib | PROT + HIST 0.314 |
| 0.385 | 0.385 | Kidney Cancer | Sorafenib | PROT + MIRNA 0.386 |
| Renal Cell Carcinoma | CAL54 | 0.347 | 0.304 | Thyroid Cancer | Vandetanib | MUT + CNV 0.339 |
| OSRC2 | 0.299 | 0.299 | Kidney Cancer | Temsirolimus | MUT + HIST 0.299 |
| TUHR14TKB | 0.308 | 0.177 | Breast Cancer | Tamoxifen | CNV + EXP 0.242 |
| UO31 | 0.310 | 0.293 | Lung Cancer | Dabrafenib | EXP + MIRNA 0.316 |
| 0.284 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + METAB 0.286 |
| 0.192 | 0.177 | Breast Cancer | Tamoxifen | CNV + HIST 0.193 |
| Leukemia | ALL | 697 | 0.464 | 0.293 | Lung Cancer | Dabrafenib | MUT + MIRNA 0.428 |
| 0.375 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + RPPA + PROT 0.374 |
| 0.263 | 0.253 | Sarcoma | Pazopanib | EXP + RPPA 0.259 |
| ALLSIL | 0.333 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP + METAB 0.332 |
| DND41 | 0.201 | 0.177 | Breast Cancer | Tamoxifen | MUT + CNV 0.115 |
| JM1 | 0.379 | 0.367 | Lymphoma | Bortezomib | MIRNA + METAB 0.376 |
| JURKAT | 0.450 | 0.299 | Kidney Cancer | Temsirolimus | PROT + RPPA 0.45 |
| 0.302 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + EXP 0.296 |
| KASUMI2 | 0.435 | 0.363 | Breast Cancer | Olaparib | MUT + CNV 0.407 |
| KE37 | 0.618 | 0.299 | Kidney Cancer | Temsirolimus | MUT + HIST 0.623 |
| MOLT13 | 0.375 | MUT + HIST 0.373 |
| MOLT16 | 0.603 | MUT + EXP 0.605 |
| NALM6 | 0.415 | CNV + EXP + PROT 0.415 |
| 0.344 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + RPPA 0.341 |
| PEER | 0.426 | 0.367 | Lymphoma | Bortezomib | HIST + RPPA 0.432 |
| 0.410 | 0.299 | Kidney Cancer | Temsirolimus | HIST + RPPA 0.412 |
| 0.289 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + METAB 0.288 |
| 0.274 | 0.253 | Sarcoma | Pazopanib | CNV + EXP + METAB 0.278 |
| PF382 | 0.498 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.497 |
| 0.383 | 0.367 | Lymphoma | Bortezomib | MUT + RPPA 0.335 |
| 0.292 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + METAB 0.292 |
| RCHACV | 0.458 | 0.299 | Kidney Cancer | Temsirolimus | PROT + HIST 0.458 |
| REH | 0.300 | EXP + RPPA 0.301 |
| RPMI8402 | 0.296 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + MIRNA 0.296 |
| RS411 | 0.373 | 0.367 | Lymphoma | Bortezomib | MUT + MIRNA 0.364 |
| 0.311 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + HIST 0.309 |
| 0.302 | 0.299 | Kidney Cancer | Temsirolimus | MUT + RPPA 0.311 |
| SEM | 0.657 | 0.282 | Pancreatic Cancer | Sunitinib | PROT + MIRNA 0.661 |
| 0.472 | 0.385 | Kidney Cancer | Sorafenib | PROT + RPPA 0.46 |
| SUPT1 | 0.387 | 0.299 | Temsirolimus | CNV + METAB 0.387 |
| SUPT11 | 0.496 | MUT + HIST 0.493 |
| TALL1 | 0.351 | CNV + HIST 0.35 |
| AML | AML193 | 0.311 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + METAB 0.311 |
| 0.198 | 0.177 | Breast Cancer | Tamoxifen | MUT + CNV 0.197 |
| BDCM | 0.307 | 0.304 | Thyroid Cancer | Vandetanib | MIRNA + METAB 0.3 |
| EOL1 | 0.992 | 0.379 | Colon/Colorectal Cancer | Regorafenib | MUT + PROT 0.991 |
| 0.991 | 0.495 | Thyroid Cancer | Cabozantinib | PROT + MIRNA 0.928 |
| 0.988 | 0.385 | Kidney Cancer | Sorafenib | PROT + MIRNA 0.99 |
| 0.987 | 0.987 | Leukemia | Nilotinib | MUT + RPPA 0.988 |
| 0.981 | 0.554 | Kidney Cancer | Axitinib | PROT + RPPA 0.913 |
| 0.967 | 0.253 | Sarcoma | Pazopanib | MUT + PROT 0.816 |
| 0.956 | 0.956 | Leukemia | Venetoclax | PROT + HIST 0.959 |
| 0.952 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + PROT 0.941 |
| 0.912 | 0.912 | Leukemia | Tretinoin | CNV + MIRNA 0.866 |
| 0.684 | 0.662 | Lymphoma | Belinostat | EXP + RPPA 0.687 |
| 0.583 | 0.304 | Thyroid Cancer | Vandetanib | MUT + PROT 0.569 |
| 0.496 | 0.496 | Leukemia | Ibrutinib | EXP + METAB 0.493 |
| 0.355 | 0.293 | Lung Cancer | Dabrafenib | PROT + METAB 0.36 |
| 0.183 | 0.177 | Breast Cancer | Tamoxifen | RPPA 0.18 |
| F36P | 0.309 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + MIRNA 0.309 |
| KASUMI1 | 0.659 | CNV + EXP 0.695 |
| 0.647 | 0.385 | Kidney Cancer | Sorafenib | PROT + RPPA 0.674 |
| 0.632 | 0.554 | Axitinib | PROT + METAB 0.566 |
| 0.589 | 0.495 | Thyroid Cancer | Cabozantinib | MUT + EXP 0.6 |
| 0.576 | 0.253 | Sarcoma | Pazopanib | PROT + HIST 0.547 |
| MOLM13 | 0.855 | 0.495 | Thyroid Cancer | Cabozantinib | MUT + PROT 0.843 |
| 0.839 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + RPPA 0.841 |
| 0.793 | 0.385 | Kidney Cancer | Sorafenib | MUT + RPPA 0.802 |
| 0.504 | 0.299 | Temsirolimus | PROT + MIRNA 0.505 |
| 0.309 | 0.253 | Sarcoma | Pazopanib | MUT + CNV 0.307 |
| MOLM16 | 0.704 | 0.495 | Thyroid Cancer | Cabozantinib | CNV + MIRNA 0.62 |
| 0.616 | 0.616 | Leukemia | Bosutinib | HIST + RPPA 0.526 |
| 0.454 | 0.282 | Pancreatic Cancer | Sunitinib | PROT + HIST 0.452 |
| MONOMAC1 | 0.541 | 0.299 | Kidney Cancer | Temsirolimus | EXP + MIRNA 0.542 |
| 0.454 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP 0.455 |
| 0.417 | 0.385 | Kidney Cancer | Sorafenib | PROT + RPPA 0.413 |
| MONOMAC6 | 0.511 | 0.495 | Thyroid Cancer | Cabozantinib | CNV + PROT 0.483 |
| 0.416 | 0.299 | Kidney Cancer | Temsirolimus | PROT 0.416 |
| 0.410 | 0.367 | Breast Cancer | Alpelisib | PROT + METAB 0.422 |
| 0.399 | 0.385 | Kidney Cancer | Sorafenib | PROT + MIRNA 0.401 |
| MV411 | 0.886 | METAB + RPPA 0.838 |
| 0.829 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP 0.842 |
| 0.655 | 0.299 | Kidney Cancer | Temsirolimus | METAB 0.644 |
| 0.524 | 0.379 | Colon/Colorectal Cancer | Regorafenib | MUT + METAB 0.522 |
| 0.477 | 0.477 | Leukemia | Idelalisib | MUT + RPPA 0.434 |
| 0.448 | 0.342 | Lymphoma | Bexarotene | EXP + MIRNA 0.441 |
| 0.264 | 0.253 | Sarcoma | Pazopanib | EXP + RPPA 0.264 |
| NOMO1 | 0.370 | 0.299 | Kidney Cancer | Temsirolimus | CNV + HIST 0.37 |
| OCIAML2 | 0.355 | 0.282 | Pancreatic Cancer | Sunitinib | HIST + RPPA 0.36 |
| OCIAML3 | 0.974 | 0.901 | Skin Cancer | Trametinib | CNV + EXP 0.861 |
| 0.414 | 0.342 | Lymphoma | Bexarotene | MUT + CNV 0.389 |
| P31FUJ | 0.390 | 0.299 | Kidney Cancer | Temsirolimus | CNV + MIRNA 0.39 |
| 0.332 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP 0.333 |
| PL21 | 0.375 | 0.299 | Kidney Cancer | Temsirolimus | CNV + HIST 0.369 |
| 0.299 | 0.282 | Pancreatic Cancer | Sunitinib | MIRNA + RPPA 0.3 |
| SIGM5 | 0.346 | 0.342 | Lymphoma | Bexarotene | MUT + EXP 0.354 |
| 0.291 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + METAB 0.291 |
| THP1 | 0.515 | 0.299 | Kidney Cancer | Temsirolimus | MUT + MIRNA 0.515 |
| CLL | JVM3 | 0.745 | CNV + MIRNA 0.732 |
| 0.186 | 0.177 | Breast Cancer | Tamoxifen | CNV + MIRNA 0.123 |
| 0.164 | 0.120 | Skin Cancer | Sonidegib | EXP + MIRNA 0.048 |
| MEC1 | 0.309 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + EXP 0.31 |
| CML | BV173 | 0.483 | 0.299 | Kidney Cancer | Temsirolimus | EXP + HIST 0.484 |
| CMLT1 | 0.456 | MUT + RPPA 0.448 |
| 0.315 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP 0.316 |
| EM2 | 0.481 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP + METAB 0.482 |
| 0.398 | 0.367 | Lymphoma | Bortezomib | MUT + EXP 0.36 |
| 0.298 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + HIST 0.297 |
| JK1 | 0.619 | 0.592 | Lung Cancer | Crizotinib | CNV + EXP 0.619 |
| 0.590 | 0.554 | Kidney Cancer | Axitinib | MUT + EXP 0.64 |
| 0.445 | 0.299 | Temsirolimus | EXP + HIST 0.445 |
| 0.396 | 0.304 | Thyroid Cancer | Vandetanib | MUT + MIRNA 0.391 |
| JURLMK1 | 0.562 | 0.554 | Kidney Cancer | Axitinib | MUT + EXP 0.55 |
| 0.430 | 0.299 | Temsirolimus | MUT + EXP 0.426 |
| 0.341 | 0.282 | Pancreatic Cancer | Sunitinib | MIRNA + METAB 0.338 |
| 0.332 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP 0.328 |
| KU812 | 0.612 | 0.554 | Kidney Cancer | Axitinib | CNV + EXP 0.616 |
| 0.388 | 0.379 | Colon/Colorectal Cancer | Regorafenib | HIST + RPPA 0.386 |
| 0.343 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP 0.337 |
| 0.342 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + MIRNA 0.345 |
| 0.322 | 0.299 | Kidney Cancer | Temsirolimus | CNV + HIST 0.326 |
| KYO1 | 0.989 | 0.989 | Leukemia | Dasatinib | EXP + MIRNA 0.913 |
| 0.309 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP 0.308 |
| LAMA84 | 0.291 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + RPPA 0.292 |
| MOLM6 | 0.328 | 0.304 | Thyroid Cancer | Vandetanib | MUT + MIRNA 0.321 |
| 0.324 | 0.299 | Kidney Cancer | Temsirolimus | MUT + METAB 0.32 |
| NCO2 | 0.433 | CNV + METAB 0.432 |
| 0.325 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + EXP 0.325 |
| 0.283 | 0.253 | Sarcoma | Pazopanib | MUT + CNV 0.288 |
| Liver Cancer |  | LI7 | 0.408 | 0.299 | Kidney Cancer | Temsirolimus | MUT 0.408 |
| 0.350 | 0.253 | Sarcoma | Pazopanib | MUT + CNV 0.272 |
| Hepatoblastoma | HUH6CLONE5 | 0.330 | 0.299 | Kidney Cancer | Temsirolimus | MUT 0.337 |
| 0.202 | 0.177 | Breast Cancer | Tamoxifen | MUT 0.121 |
| Hepatocellular Carcinoma | HUH1 | 0.287 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + PROT 0.289 |
| SNU182 | 0.413 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.412 |
| 0.305 | 0.304 | Thyroid Cancer | Vandetanib | CNV + METAB 0.305 |
| 0.285 | 0.282 | Pancreatic Cancer | Sunitinib | MIRNA + METAB 0.286 |
| SNU398 | 0.327 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + HIST 0.328 |
| SNU761 | 0.411 | CNV + EXP 0.394 |
| 0.330 | 0.177 | Breast Cancer | Tamoxifen | MUT + EXP 0.31 |
| SNU878 | 0.405 | 0.299 | Kidney Cancer | Temsirolimus | HIST + RPPA 0.399 |
| SNU886 | 0.287 | 0.253 | Sarcoma | Pazopanib | CNV + EXP 0.304 |
| Lung Cancer | NSCLC | CAL12T | 0.314 | 0.177 | Breast Cancer | Tamoxifen | CNV + EXP 0.158 |
| 0.306 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP 0.271 |
| 0.143 | 0.120 | Skin Cancer | Sonidegib | METAB + HIST 0.044 |
| CALU3 | 0.512 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + HIST 0.51 |
| 0.185 | 0.177 | Breast Cancer | Tamoxifen | CNV + MIRNA 0.173 |
| CALU6 | 0.394 | 0.299 | Kidney Cancer | Temsirolimus | CNV + METAB 0.333 |
| DV90 | 0.392 | 0.363 | Breast Cancer | Olaparib | CNV + MIRNA 0.313 |
| 0.334 | 0.304 | Thyroid Cancer | Vandetanib | PROT + MIRNA 0.341 |
| EBC1 | 0.543 | 0.299 | Kidney Cancer | Temsirolimus | MUT + CNV 0.55 |
| EKVX | 0.335 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP + METAB 0.335 |
| 0.198 | 0.177 | Breast Cancer | Tamoxifen | CNV + EXP 0.185 |
| EPLC272H | 0.555 | 0.496 | Leukemia | Ibrutinib | MUT + EXP 0.517 |
| 0.458 | 0.367 | Breast Cancer | Alpelisib | CNV + EXP 0.476 |
| 0.435 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.439 |
| HCC1195 | 0.362 | MUT + EXP 0.366 |
| HCC1833 | 0.329 | MUT 0.322 |
| 0.178 | 0.177 | Breast Cancer | Tamoxifen | EXP 0.142 |
| HCC2935 | 0.497 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP 0.446 |
| HCC4006 | 0.572 | 0.496 | Leukemia | Ibrutinib | CNV + EXP 0.573 |
| 0.410 | 0.304 | Thyroid Cancer | Vandetanib | METAB + RPPA 0.405 |
| HCC44 | 0.488 | 0.299 | Kidney Cancer | Temsirolimus | CNV + MIRNA 0.485 |
| HCC78 | 0.172 | 0.120 | Skin Cancer | Sonidegib | MUT + HIST 0.034 |
| HCC827 | 0.849 | 0.849 | Lung Cancer | Gefitinib | HIST + RPPA 0.818 |
| 0.520 | 0.304 | Thyroid Cancer | Vandetanib | EXP + RPPA + HIST + PROT 0.52 |
| HOP92 | 0.293 | 0.293 | Lung Cancer | Dabrafenib | MIRNA + METAB 0.3 |
| 0.180 | 0.177 | Breast Cancer | Tamoxifen | MUT + EXP 0.186 |
| 0.159 | 0.120 | Skin Cancer | Sonidegib | CNV + RPPA 0.099 |
| LC1F | 0.405 | 0.385 | Kidney Cancer | Sorafenib | CNV 0.226 |
| LCLC97TM1 | 0.404 | 0.299 | Temsirolimus | EXP + MIRNA 0.408 |
| LU65 | 0.187 | 0.120 | Skin Cancer | Sonidegib | MUT + EXP 0.154 |
| NCIH1155 | 0.374 | 0.299 | Kidney Cancer | Temsirolimus | EXP + MIRNA 0.374 |
| NCIH1355 | 0.440 | MUT + CNV 0.434 |
| NCIH1385 | 0.177 | 0.177 | Breast Cancer | Tamoxifen | MUT + CNV 0.181 |
| NCIH1435 | 0.380 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP + METAB 0.379 |
| NCIH1563 | 0.120 | 0.120 | Skin Cancer | Sonidegib | MUT + EXP 0.058 |
| NCIH1568 | 0.178 | 0.177 | Breast Cancer | Tamoxifen | EXP + RPPA + HIST + PROT 0.14 |
| NCIH1581 | 0.468 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.468 |
| 0.320 | 0.253 | Sarcoma | Pazopanib | CNV + PROT 0.318 |
| 0.196 | 0.177 | Breast Cancer | Tamoxifen | EXP + MIRNA 0.195 |
| NCIH1623 | 0.427 | 0.367 | Alpelisib | EXP + METAB 0.347 |
| NCIH1650 | 0.307 | 0.304 | Thyroid Cancer | Vandetanib | MUT + PROT 0.311 |
| NCIH1666 | 0.461 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP + PROT + METAB 0.458 |
| 0.395 | 0.304 | Thyroid Cancer | Vandetanib | METAB + HIST 0.395 |
| 0.228 | 0.177 | Breast Cancer | Tamoxifen | MUT + EXP 0.231 |
| NCIH1693 | 0.380 | 0.304 | Thyroid Cancer | Vandetanib | PROT + MIRNA 0.376 |
| NCIH1703 | 0.596 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + PROT 0.644 |
| 0.555 | 0.554 | Kidney Cancer | Axitinib | CNV + EXP 0.569 |
| 0.525 | 0.495 | Thyroid Cancer | Cabozantinib | PROT + MIRNA 0.534 |
| 0.482 | 0.385 | Kidney Cancer | Sorafenib | EXP + PROT 0.435 |
| 0.476 | 0.253 | Sarcoma | Pazopanib | MUT + PROT 0.47 |
| 0.404 | 0.379 | Colon/Colorectal Cancer | Regorafenib | PROT + MIRNA 0.41 |
| 0.367 | 0.304 | Thyroid Cancer | Vandetanib | MUT + PROT 0.34 |
| NCIH1734 | 0.469 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP + METAB 0.47 |
| 0.327 | 0.304 | Thyroid Cancer | Vandetanib | MUT + EXP 0.331 |
| NCIH1755 | 0.305 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + HIST 0.304 |
| NCIH1793 | 0.177 | 0.177 | Breast Cancer | Tamoxifen | CNV + PROT 0.18 |
| NCIH2023 | 0.321 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + METAB 0.323 |
| NCIH2085 | 0.305 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP 0.287 |
| NCIH2087 | 0.473 | 0.299 | Kidney Cancer | Temsirolimus | CNV + METAB 0.495 |
| 0.314 | 0.282 | Pancreatic Cancer | Sunitinib | MIRNA + METAB + HIST + RPPA 0.313 |
| 0.213 | 0.177 | Breast Cancer | Tamoxifen | CNV + EXP 0.227 |
| NCIH2106 | 0.195 | CNV + MIRNA 0.203 |
| NCIH226 | 0.230 | CNV + PROT 0.189 |
| 0.137 | 0.120 | Skin Cancer | Sonidegib | EXP + RPPA + HIST + PROT 0.057 |
| NCIH2405 | 0.341 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + EXP 0.305 |
| NCIH2444 | 0.365 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.36 |
| 0.351 | 0.177 | Breast Cancer | Tamoxifen | MUT + CNV 0.199 |
| 0.153 | 0.120 | Skin Cancer | Sonidegib | CNV + HIST 0.055 |
| NCIH292 | 0.446 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP 0.447 |
| NCIH358 | 0.475 | PROT + HIST 0.487 |
| 0.316 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP + METAB 0.316 |
| NCIH520 | 0.397 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP + PROT 0.397 |
| NCIH661 | 0.370 | CNV + METAB 0.366 |
| PC14 | 0.812 | 0.812 | Lung Cancer | Erlotinib | MUT + PROT 0.74 |
| 0.622 | 0.616 | Leukemia | Bosutinib | EXP + PROT 0.613 |
| 0.597 | 0.304 | Thyroid Cancer | Vandetanib | MUT + EXP 0.602 |
| 0.149 | 0.120 | Skin Cancer | Sonidegib | CNV + EXP 0.066 |
| SCLC | CORL279 | 0.406 | 0.363 | Breast Cancer | Olaparib | MUT + METAB 0.39 |
| CORL51 | 0.289 | 0.282 | Pancreatic Cancer | Sunitinib | CNV 0.251 |
| DMS454 | 0.297 | METAB 0.285 |
| NCIH1092 | 0.191 | 0.120 | Skin Cancer | Sonidegib | MUT + CNV 0.076 |
| NCIH1184 | 0.487 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.483 |
| 0.128 | 0.120 | Skin Cancer | Sonidegib | CNV + HIST 0.066 |
| NCIH2081 | 0.155 | MUT + EXP 0.098 |
| NCIH211 | 0.550 | 0.299 | Kidney Cancer | Temsirolimus | MUT + METAB 0.544 |
| 0.208 | 0.177 | Breast Cancer | Tamoxifen | MUT + CNV 0.208 |
| NCIH2141 | 0.147 | 0.120 | Skin Cancer | Sonidegib | MUT + CNV 0.173 |
| NCIH2286 | 0.366 | 0.299 | Kidney Cancer | Temsirolimus | CNV + MIRNA 0.366 |
| NCIH446 | 0.321 | MUT + EXP 0.32 |
| NCIH524 | 0.300 | MUT + EXP 0.3 |
| NCIH889 | 0.335 | CNV + MIRNA 0.344 |
| SBC5 | 0.168 | 0.120 | Skin Cancer | Sonidegib | MUT + CNV 0.081 |
| SW1271 | 0.393 | 0.299 | Kidney Cancer | Temsirolimus | PROT + RPPA 0.388 |
| 0.229 | 0.177 | Breast Cancer | Tamoxifen | MUT + CNV 0.187 |
| Lung Carcinoid | NCIH727 | 0.329 | 0.299 | Kidney Cancer | Temsirolimus | METAB 0.337 |
| Mesothelioma | MSTO211H | 0.621 | CNV + MIRNA 0.614 |
| 0.310 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + PROT 0.309 |
| NCIH2452 | 0.580 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + METAB 0.553 |
| NCIH28 | 0.335 | CNV 0.335 |
| Lymphoma | Hodgkin Lymphoma | HDLM2 | 0.379 | CNV + METAB 0.376 |
| 0.283 | 0.282 | Pancreatic Cancer | Sunitinib | MIRNA + RPPA 0.282 |
| HS611T | 0.308 | MIRNA + METAB 0.306 |
| KMH2 | 0.367 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + METAB 0.359 |
| L428 | 0.182 | 0.177 | Breast Cancer | Tamoxifen | PROT + METAB 0.152 |
| L540 | 0.545 | 0.299 | Kidney Cancer | Temsirolimus | MUT + MIRNA 0.546 |
| Lymphoma Unspecified | EHEB | 0.491 | CNV 0.492 |
| Non Hodgkin Lymphoma | A3KAW | 0.301 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP 0.299 |
| A4FUK | 0.323 | HIST 0.321 |
| CA46 | 0.262 | 0.253 | Sarcoma | Pazopanib | EXP 0.252 |
| DB | 0.367 | 0.367 | Lymphoma | Bortezomib | CNV + METAB 0.366 |
| DEL | 0.324 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + CNV 0.325 |
| DOHH2 | 0.483 | 0.363 | Breast Cancer | Olaparib | EXP + METAB 0.484 |
| 0.444 | 0.299 | Kidney Cancer | Temsirolimus | RPPA 0.471 |
| EB1 | 0.307 | 0.304 | Thyroid Cancer | Vandetanib | CNV + MIRNA 0.313 |
| 0.285 | 0.282 | Pancreatic Cancer | Sunitinib | METAB + HIST 0.286 |
| 0.272 | 0.253 | Sarcoma | Pazopanib | EXP + METAB 0.275 |
| GA10 | 0.662 | 0.662 | Lymphoma | Belinostat | EXP + METAB 0.658 |
| 0.295 | 0.293 | Lung Cancer | Dabrafenib | CNV + HIST 0.299 |
| 0.289 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + METAB 0.286 |
| 0.264 | 0.253 | Sarcoma | Pazopanib | CNV + METAB 0.265 |
| HT | 0.616 | 0.299 | Kidney Cancer | Temsirolimus | CNV + MIRNA 0.621 |
| HUT78 | 0.342 | 0.342 | Lymphoma | Bexarotene | CNV + EXP + METAB 0.369 |
| JVM2 | 0.466 | 0.466 | Vorinostat | MUT + EXP 0.378 |
| KARPAS299 | 0.596 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + METAB 0.594 |
| 0.368 | 0.282 | Pancreatic Cancer | Sunitinib | PROT + RPPA 0.358 |
| KIJK | 0.659 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.658 |
| 0.368 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP 0.344 |
| NUDHL1 | 0.345 | 0.293 | Lung Cancer | Dabrafenib | PROT + MIRNA 0.349 |
| NUDUL1 | 0.629 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.63 |
| 0.318 | 0.282 | Pancreatic Cancer | Sunitinib | HIST + RPPA 0.318 |
| OCILY19 | 0.298 | MUT + METAB 0.297 |
| PFEIFFER | 0.534 | 0.496 | Leukemia | Ibrutinib | MUT + CNV 0.552 |
| 0.467 | 0.293 | Lung Cancer | Dabrafenib | CNV + EXP 0.462 |
| 0.422 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + HIST 0.421 |
| 0.360 | 0.304 | Thyroid Cancer | Vandetanib | MIRNA + METAB 0.349 |
| 0.334 | 0.253 | Sarcoma | Pazopanib | EXP + MIRNA 0.333 |
| RI1 | 0.704 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP 0.706 |
| 0.699 | 0.496 | Leukemia | Ibrutinib | CNV + EXP 0.595 |
| 0.644 | 0.477 | Idelalisib | CNV + EXP 0.517 |
| 0.295 | 0.282 | Pancreatic Cancer | Sunitinib | CNV 0.295 |
| SR786 | 0.612 | 0.299 | Kidney Cancer | Temsirolimus | MUT + CNV 0.614 |
| SUDHL1 | 0.347 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + HIST 0.344 |
| SUDHL4 | 0.540 | 0.299 | Kidney Cancer | Temsirolimus | CNV + PROT 0.544 |
| SUDHL6 | 0.746 | MIRNA + RPPA 0.746 |
| 0.725 | 0.477 | Leukemia | Idelalisib | CNV + EXP 0.538 |
| 0.177 | 0.177 | Breast Cancer | Tamoxifen | CNV + PROT 0.189 |
| SUDHL8 | 0.617 | 0.299 | Kidney Cancer | Temsirolimus | EXP + METAB 0.611 |
| SUPM2 | 0.389 | 0.363 | Breast Cancer | Olaparib | CNV + EXP 0.387 |
| 0.292 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + METAB 0.292 |
| WSUDLCL2 | 0.676 | 0.299 | Kidney Cancer | Temsirolimus | EXP + MIRNA 0.669 |
| 0.133 | 0.120 | Skin Cancer | Sonidegib | MIRNA + HIST 0.041 |
| Myeloma | Multiple Myeloma | AMO1 | 0.415 | 0.367 | Lymphoma | Bortezomib | MIRNA + METAB + HIST + RPPA 0.321 |
| EJM | 0.120 | 0.120 | Skin Cancer | Sonidegib | MUT + EXP 0.117 |
| KE97 | 0.589 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + RPPA 0.593 |
| 0.311 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + EXP 0.31 |
| KHM1B | 0.471 | 0.299 | Kidney Cancer | Temsirolimus | EXP + RPPA 0.472 |
| 0.343 | 0.282 | Pancreatic Cancer | Sunitinib | MIRNA + RPPA 0.342 |
| 0.184 | 0.177 | Breast Cancer | Tamoxifen | MUT + EXP 0.112 |
| KMS11 | 0.515 | 0.299 | Kidney Cancer | Temsirolimus | EXP + RPPA + HIST + PROT 0.518 |
| 0.367 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + PROT 0.361 |
| 0.281 | 0.253 | Sarcoma | Pazopanib | MIRNA + HIST 0.283 |
| KMS12BM | 0.539 | 0.299 | Kidney Cancer | Temsirolimus | EXP + PROT 0.537 |
| 0.202 | 0.177 | Breast Cancer | Tamoxifen | PROT + RPPA 0.204 |
| KMS18 | 0.445 | 0.299 | Kidney Cancer | Temsirolimus | MUT + MIRNA 0.446 |
| KMS20 | 0.380 | 0.367 | Breast Cancer | Alpelisib | CNV + RPPA 0.359 |
| 0.357 | 0.293 | Lung Cancer | Dabrafenib | MUT + MIRNA 0.32 |
| 0.182 | 0.177 | Breast Cancer | Tamoxifen | MUT + CNV 0.168 |
| KMS21BM | 0.669 | 0.299 | Kidney Cancer | Temsirolimus | CNV 0.686 |
| 0.435 | 0.367 | Lymphoma | Bortezomib | CNV + EXP 0.41 |
| 0.303 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + HIST 0.304 |
| 0.268 | 0.253 | Sarcoma | Pazopanib | CNV + EXP + METAB 0.266 |
| 0.200 | 0.177 | Breast Cancer | Tamoxifen | HIST + RPPA 0.189 |
| KMS26 | 0.837 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + METAB 0.778 |
| 0.332 | 0.253 | Sarcoma | Pazopanib | EXP + MIRNA 0.334 |
| KMS27 | 0.413 | 0.299 | Kidney Cancer | Temsirolimus | MUT + PROT 0.41 |
| KMS28BM | 0.470 | CNV + EXP 0.468 |
| KMS34 | 0.824 | MUT + MIRNA 0.818 |
| 0.384 | 0.367 | Breast Cancer | Alpelisib | MIRNA + RPPA 0.386 |
| L363 | 0.650 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + HIST 0.645 |
| LP1 | 0.379 | 0.367 | Breast Cancer | Alpelisib | MUT + EXP 0.386 |
| 0.295 | 0.253 | Sarcoma | Pazopanib | MUT + EXP 0.299 |
| MM1S | 0.523 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.522 |
| 0.293 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + EXP 0.292 |
| MOLP2 | 0.391 | 0.299 | Kidney Cancer | Temsirolimus | EXP + RPPA 0.39 |
| MOLP8 | 0.291 | 0.282 | Pancreatic Cancer | Sunitinib | METAB + HIST 0.291 |
| NCIH929 | 0.457 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP + PROT 0.456 |
| 0.408 | 0.367 | Lymphoma | Bortezomib | PROT + HIST 0.403 |
| 0.369 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + RPPA + HIST + PROT 0.361 |
| OPM2 | 0.462 | 0.367 | Lymphoma | Bortezomib | PROT + MIRNA 0.455 |
| 0.348 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + PROT 0.348 |
| RPMI8226 | 0.426 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP 0.422 |
| Neuroblastoma | Neuroblastoma | IMR32 | 0.694 | 0.662 | Lymphoma | Belinostat | CNV + EXP 0.695 |
| 0.369 | 0.363 | Breast Cancer | Olaparib | EXP + RPPA 0.364 |
| KELLY | 0.329 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.326 |
| KPNSI9S | 0.389 | MIRNA + METAB 0.389 |
| MHHNB11 | 0.304 | 0.282 | Pancreatic Cancer | Sunitinib | MIRNA + HIST 0.305 |
| NB1 | 0.311 | 0.299 | Kidney Cancer | Temsirolimus | EXP + METAB 0.308 |
| 0.298 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + HIST 0.291 |
| SKNDZ | 0.216 | 0.177 | Breast Cancer | Tamoxifen | CNV + MIRNA 0.18 |
| Ovarian Cancer | Brenner Tumor | SNU840 | 0.463 | 0.299 | Kidney Cancer | Temsirolimus | MUT + RPPA 0.463 |
| Ovary Adenocarcinoma | A2780 | 0.622 | CNV + EXP 0.621 |
| 0.419 | 0.367 | Breast Cancer | Alpelisib | CNV + PROT 0.416 |
| CAOV3 | 0.344 | 0.299 | Kidney Cancer | Temsirolimus | EXP + PROT 0.344 |
| COV434 | 0.310 | 0.282 | Pancreatic Cancer | Sunitinib | EXP + MIRNA 0.311 |
| 0.232 | 0.177 | Breast Cancer | Tamoxifen | CNV + MIRNA 0.182 |
| FUOV1 | 0.300 | 0.282 | Pancreatic Cancer | Sunitinib | MUT + CNV 0.295 |
| IGROV1 | 0.336 | 0.299 | Kidney Cancer | Temsirolimus | CNV + METAB 0.336 |
| 0.297 | 0.282 | Pancreatic Cancer | Sunitinib | PROT + MIRNA 0.3 |
| MCAS | 0.205 | 0.120 | Skin Cancer | Sonidegib | CNV + MIRNA 0.033 |
| OAW28 | 0.361 | 0.299 | Kidney Cancer | Temsirolimus | MUT + HIST 0.349 |
| OV7 | 0.402 | 0.385 | Sorafenib | MUT + EXP 0.258 |
| 0.279 | 0.253 | Sarcoma | Pazopanib | MUT + EXP 0.201 |
| OV90 | 0.397 | 0.293 | Lung Cancer | Dabrafenib | CNV + EXP 0.346 |
| OVK18 | 0.537 | 0.299 | Kidney Cancer | Temsirolimus | CNV + RPPA 0.537 |
| RMGI | 0.350 | MUT + MIRNA 0.35 |
| SNU119 | 0.343 | EXP + PROT 0.343 |
| SNU8 | 0.403 | MIRNA + HIST 0.405 |
| TYKNU | 0.356 | EXP + RPPA + PROT 0.357 |
| Pancreatic Cancer | Exocrine | BXPC3 | 0.343 | EXP + MIRNA 0.346 |
| HS766T | 0.282 | 0.282 | Pancreatic Cancer | Sunitinib | MIRNA + METAB + HIST + RPPA 0.28 |
| HUPT4 | 0.362 | 0.304 | Thyroid Cancer | Vandetanib | MUT + RPPA 0.362 |
| 0.301 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + METAB 0.302 |
| PANC0504 | 0.340 | CNV + EXP 0.34 |
| PATU8988S | 0.510 | 0.304 | Thyroid Cancer | Vandetanib | MIRNA + METAB 0.313 |
| PK59 | 0.396 | 0.299 | Kidney Cancer | Temsirolimus | MUT + EXP 0.398 |
| SU8686 | 0.348 | MIRNA + HIST 0.346 |
| 0.252 | 0.177 | Breast Cancer | Tamoxifen | MUT + CNV 0.234 |
| Prostate Cancer | Prostate Adenocarcinoma | 22RV1 | 0.464 | 0.299 | Kidney Cancer | Temsirolimus | PROT + MIRNA 0.464 |
| Rhabdoid | Malignant Rhabdoid Tumor | A204 | 0.597 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + PROT 0.609 |
| 0.594 | 0.554 | Kidney Cancer | Axitinib | MUT + EXP 0.43 |
| 0.473 | 0.253 | Sarcoma | Pazopanib | CNV + EXP 0.424 |
| 0.436 | 0.385 | Kidney Cancer | Sorafenib | MIRNA + METAB 0.437 |
| 0.404 | 0.379 | Colon/Colorectal Cancer | Regorafenib | PROT + METAB 0.405 |
| 0.188 | 0.177 | Breast Cancer | Tamoxifen | CNV + EXP + PROT + METAB 0.184 |
| TTC709 | 0.284 | 0.253 | Sarcoma | Pazopanib | MUT + EXP 0.324 |
| Sarcoma | Rhabdomyosarcoma | RH18 | 0.357 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + METAB 0.356 |
| RH41 | 0.406 | PROT + METAB 0.407 |
| 0.349 | 0.282 | Pancreatic Cancer | Sunitinib | PROT + MIRNA 0.35 |
| 0.253 | 0.253 | Sarcoma | Pazopanib | MIRNA + METAB 0.254 |
| TE617T | 0.670 | 0.496 | Leukemia | Ibrutinib | MUT + EXP 0.545 |
| 0.312 | 0.304 | Thyroid Cancer | Vandetanib | EXP + METAB 0.318 |
| Skin Cancer | Melanoma | COLO829 | 0.520 | 0.293 | Lung Cancer | Dabrafenib | PROT + RPPA 0.533 |
| HS294T | 0.314 | EXP + RPPA + PROT 0.313 |
| HS852T | 0.396 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + HIST 0.395 |
| HT144 | 0.521 | 0.293 | Lung Cancer | Dabrafenib | CNV + EXP 0.493 |
| IGR1 | 0.402 | PROT + RPPA 0.388 |
| IGR37 | 0.302 | CNV + EXP 0.303 |
| K029AX | 0.385 | MUT + RPPA 0.382 |
| LOXIMVI | 0.406 | PROT + MIRNA 0.364 |
| MELHO | 0.437 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP 0.443 |
| RVH421 | 0.409 | 0.293 | Lung Cancer | Dabrafenib | CNV + EXP + PROT + METAB 0.404 |
| SH4 | 0.674 | MUT + EXP 0.604 |
| 0.215 | 0.177 | Breast Cancer | Tamoxifen | EXP + MIRNA 0.187 |
| 0.120 | 0.120 | Skin Cancer | Sonidegib | CNV + MIRNA 0.118 |
| SKMEL1 | 0.374 | 0.299 | Kidney Cancer | Temsirolimus | MIRNA + HIST 0.376 |
| SKMEL24 | 0.622 | 0.293 | Lung Cancer | Dabrafenib | CNV + EXP 0.565 |
| SKMEL3 | 0.311 | CNV + EXP 0.309 |
| UACC257 | 0.613 | CNV + EXP 0.624 |
| WM115 | 0.755 | EXP + PROT 0.793 |
| 0.360 | 0.360 | Skin Cancer | Vemurafenib | MUT + CNV 0.359 |
| WM1799 | 0.303 | 0.299 | Kidney Cancer | Temsirolimus | CNV + EXP + PROT 0.305 |
| WM2664 | 0.575 | 0.293 | Lung Cancer | Dabrafenib | MUT + MIRNA 0.572 |
| WM88 | 0.901 | 0.901 | Skin Cancer | Trametinib | CNV + EXP 0.893 |
| WM983B | 0.578 | 0.293 | Lung Cancer | Dabrafenib | CNV + EXP 0.572 |
| Thyroid Cancer | Thyroid Carcinoma | 8305C | 0.434 | 0.299 | Kidney Cancer | Temsirolimus | CNV + PROT 0.431 |
| 8505C | 0.325 | CNV + MIRNA 0.32 |
| CAL62 | 0.338 | CNV + EXP 0.333 |
| CGTHW1 | 0.467 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + MIRNA 0.304 |
| 0.345 | 0.253 | Sarcoma | Pazopanib | MUT + METAB 0.331 |
| 0.331 | 0.299 | Kidney Cancer | Temsirolimus | CNV + MIRNA 0.331 |
| ML1 | 0.488 | MUT + EXP 0.452 |
| TT2609C02 | 0.283 | 0.253 | Sarcoma | Pazopanib | CNV + MIRNA 0.144 |
| Thyroid Squamous | SW579 | 0.531 | 0.282 | Pancreatic Cancer | Sunitinib | CNV + EXP 0.54 |
| 0.495 | 0.495 | Thyroid Cancer | Cabozantinib | MUT + CNV 0.49 |
| 0.469 | 0.253 | Sarcoma | Pazopanib | MUT + EXP 0.331 |
| 0.455 | 0.385 | Kidney Cancer | Sorafenib | MUT + MIRNA 0.466 |
| 0.380 | 0.379 | Colon/Colorectal Cancer | Regorafenib | MUT + METAB 0.399 |
| 0.304 | 0.304 | Thyroid Cancer | Vandetanib | CNV + EXP 0.3 |
| TT | 0.270 | 0.177 | Breast Cancer | Tamoxifen | EXP + MIRNA 0.168 |